21 results on '"Mannent, L.P."'
Search Results
2. 650 Dupilumab significantly improves itch and skin lesions in patients with prurigo nodularis: Pooled results from two phase 3 trials (liberty-pn prime and prime2)
3. Dupilumab efficacy and safety up to 52 weeks in adult and adolescent patients with eosinophilic esophagitis: Results from parts B and C of the randomized, placebo-controlled, three-part, phase 3 LIBERTY EoE TREET Study
4. Le dupilumab réduit significativement démangeaisons et urticaire chez des patients souffrant d’urticaire chronique spontané (UCS) qui demeurent symptomatiques malgré un traitement standard par antihistaminiques : résultats d’une étude de phase 3
5. Dupilumab Impact on Lung Function in Children with Uncontrolled, Moderate-To-Severe Asthma and Elevated Type 2 Biomarkers
6. Dupilumab safety and efficacy up to 52 weeks in adult and adolescent patients with eosinophilic esophagitis: Results from part A and C of a randomized, placebo-controlled, three-part, phase 3 LIBERTY EoE TREET Study
7. Efficacité et tolérance du dupilumab chez les enfants souffrant d’asthme modéré à sévère non contrôlé : étude de phase 3 VOYAGE
8. Efficacité à long terme à trois ans du dupilumab chez les patients QUEST recrutés dans l’étude LIBERTY ASTHMA TRAVERSE
9. Évaluation du profil de sécurité du rilzabrutinib à 12 semaines chez des patients atteints d’urticaire chronique spontanée dans l’étude de phase 2 de recherche de dose RILECSU
10. Traitement par dupilumab chez des patients atteints de dermatite atopique des mains et des pieds: résultats d’une étude de phase 3, randomisée, en double aveugle et contrôlée par placebo
11. Long-Term 3-Year Efficacy of Dupilumab in QUEST Patients Enrolled in LIBERTY ASTHMA TRAVERSE
12. 434 The study design of two trials of dupilumab in patients with prurigo nodularis inadequately controlled with topical therapies: LIBERTY PN PRIME and PRIME 2
13. Dupilumab Efficacy and Safety in Children with Uncontrolled, Moderate-to-Severe Asthma: The Phase 3 VOYAGE Study
14. Assessment of Long-Term Maintenance of OCS Reduction and Efficacy in the Dupilumab LIBERTY ASTHMA TRAVERSE Extension Study
15. Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP
16. Dupilumab Efficacy in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma by Baseline IgE and Thymus and Activation Regulated Chemokine Levels from the Pooled Population of the SINUS-24 and SINUS-52 Phase 3 Trials
17. Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma from the Pooled Populations of the SINUS-24 and SINUS-52 Dupilumab Phase 3 Trials
18. Lung Function in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Comorbid Asthma with Clinical Features of Chronic Obstructive Pulmonary Disease (COPD): Pooled Analysis of the Phase 3 SINUS-24 and SINUS-52 Studies
19. Dupilumab Improves Asthma Control as Assessed by Total and Individual Item Scores of the 6-Item Asthma Control Questionnaire in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Studies
20. Dupilumab Improves Upper and Lower Airway Outcome Measures in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma: Pooled Results from the SINUS-24 and SINUS-52 Phase 3 Studies
21. The GALEN rhinosinusitis cohort: chronic rhinosinusitis with nasal polyps affects health-related quality of life
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.